Table 1.
Characteristics of men whose partners reported pregnancy after hematopoietic-cell transplantation
| Characteristic | Malignant diseases |
Non-Malignant diseases N (%) | ||
|---|---|---|---|---|
| Autologous N (%) | Allogeneic Myeloablative N (%) | Allogeneic Non-Myeloablative N (%) | ||
| Number of patients | 13 | 50 | 2 | 30 |
| Median age at HCT (range), years | 28 (20-40) | 25 (5-53) | (30-49) | 22 (4-34) |
| Age at HCT, years | ||||
| <10 | 0 | 1 (2) | 0 | 2 (7) |
| 10-19 | 1 (8) | 5 (10) | 0 | 9 (30) |
| 20-29 | 7 (54) | 32 (64) | 1 | 14 (47) |
| 30-39 | 4 (31) | 11 (22) | 0 | 5 (17) |
| 40-49 | 1 (8) | 0 | 1 | 0 |
| ≥50 | 0 | 1 (2) | 0 | 0 |
| Diagnosis | ||||
| Acute myeloid leukemia† | 2 (15) | 17 (34) | 1 | 0 |
| Acute lymphoblastic leukemia† | 1 (8) | 5 (10) | 0 | 0 |
| Chronic myeloid leukemia | 0 | 22 (44) | 0 | 0 |
| Myelodysplastic syndrome | 0 | 5 (10) | 1 | 0 |
| Lymphoma | 7 (53) | 1 (2) | 0 | 0 |
| Multiple myeloma | 1 (8) | 0 | 0 | 0 |
| Solid Cancer | 2 (15) | 0 | 0 | 0 |
| Severe aplastic anemia | 0 | 0 | 0 | 30 (100) |
| Chemotherapy prior to conditioning regimen | 13 (100) | 45 (96) | 2 | 0 |
| Radiation therapy prior to conditioning regimen | 3 (23) | 0 | 0 | 0 |
| Year of HCT | ||||
| ≤1989 | 0 | 6 (12) | 0 | 5 (17) |
| 1990-1994 | 2 (15) | 17 (34) | 0 | 12 (40) |
| 1995-1999 | 6 (46) | 13 (26) | 0 | 5 (17) |
| ≥2000 | 5 (38) | 14 (28) | 2 | 8 (27) |
| Conditioning regimen | ||||
| TBI + Cyclophosphamide ± Other | 0 | 14 (28) | 0 | 0 |
| Busulfan + Cyclophosphamide ± Other‡ | 2 (15) | 32 (64) | 0 | 5 (17) |
| Cyclophosphamide ± Other (no TBI or Busulfan) | 8 (62) | 0 | 1 | 24 (80) |
| Other | 3 (23) | 4 (8) | 1 | 1 (3) |
| TBI in conditioning | ||||
| Median dose (range), cGy | 1320 | 1200 (400-1440) | 200 | - |
| TBI dose, cGy | ||||
| No TBI | 12 (92) | 33 (66) | 1 | 30 (100) |
| <400 | 0 | 0 | 1 | - |
| 400-800 | 0 | 3 (6) | 0 | - |
| >800 | 1 (8) | 14 (28) | 0 | - |
| Cyclophosphamide dose, mg/kg | ||||
| No cyclophosphamide | 3 (23) | 4 (8) | 1 | 1 (3) |
| ≤120 | 2 (15) | 30 (63) | 1 | 4 (13) |
| >120 | 8 (62) | 14 (29) | 0 | 25 (83) |
| Missing | 0 | 2 | 0 | 0 |
| Donor type | ||||
| Autologous | 13 (100) | 0 | 0 | 0 |
| HLA-matched Siblings | 0 | 37 (74) | 2 | 28 (90) |
| Other related | 0 | 3 (6) | 0 | 1 (3) |
| Unrelated donor | 0 | 10 (20) | 0 | 1 (3) |
| Acute GVHD at any time after HCT | - | 17 (34) | 0 | 4 (13) |
| Chronic GVHD at any time after HCT | - | 29 (58) | 1 | 11 (37) |
| Relapse after HCT* | 5 (38) | 10 (20) | 1 | - |
| Median time from HCT to relapse (range), months | 7 (<1-62) | 17 (<1-144) | 1 | - |
| Second transplant or DLI for relapse | 2 (15) | 3 (6) | 1 | 0 |
| Disease status at last followup | ||||
| Continued complete remission | 8 (62) | 40 (80) | 1 | 0 |
| Complete remission after relapse | 1 (8) | 9 (18) | 0 | 0 |
| Recurrent disease | 4 (31) | 1 (2) | 1 | 0 |
| Cured | 0 | 0 | 0 | 30 (100) |
| Median followup (range), years | 8 (2-15) | 10 (3-19) | (2-5) | 11 (2-22) |
HCT – hematopoietic-cell transplantation, TBI – total body irradiation, GVHD – graft versus host disease, DLI – donor lymphocyte infusion
*
For malignant diseases only
†
18/20 patients with acute myeloid leukemia and 5/6 patients with acute lymphoblastic leukemia had received HCT in first complete remission
‡
Among 32 men who received myeloablative busulfan + cyclophosphamide +/- other as conditioning, 5 (16%) reported use of cryo-preserved sperm, 17 (53%) fathered a child naturally and information about sperm storage was missing in 10 (31%)